Aetna considers medical treatment of rosacea medically necessary.  However, surgical treatment of disfigurement from rosacea (e.g., rhinophyma, scarring and telangiectasias) is considered cosmetic.

See CPB 0559 - Pulsed Dye Laser Treatment.

Note: Cosmetic surgery is excluded from coverage under Aetna standard benefit plans.  Please check benefit plan descriptions for details.  See CPB 0031 - Cosmetic Surgery.

Rosacea is a multi-factorial skin disorder that usually affects middle-aged individuals and is characterized by persistent erythema, telangiectasias and acute episodes of edema, papules, and pustules.  Patients may have a tendency to flush easily.  Treatment is difficult and is dependent on the severity of disease.  Avoidance of excessive sunlight and extreme temperatures is typically recommended.  Medical management is aimed only at the inflammatory papules and pustules and the erythema that surrounds them.  Topical preparations of metronidazole, clindamycin and erythromycin have been shown to be helpful for mild cases.  Oral tetracycline and erythromycin are often prescribed for moderate cases, and Accutane (isotretinoin) has been found to be effective in severe refractory cases.  Oral metronidazole has also been used in severe refractory cases.

Accepted guidelines indicate that laser surgery and electrocautery are the only satisfactory treatments for the telangiectasias.  Treatment is directed toward obliteration of ectatic vessels.  Rhinophyma (soft tissue and sebaceous hyperplasia of the nose) is considered the culmination of acne rosacea.  Rhinophyma responds to electrosurgery, laser excision, and surgical debulking.  Because telangiectasias and rhinophyma do not cause functional limitations, their treatment is considered cosmetic. 

Goldberg (2005) stated that pharmacological agents remain the mainstay for initial and maintenance treatment of rosacea.  However, monochromatic (i.e., laser) and polychromatic light-based therapies are increasingly being used for the treatment of certain signs of rosacea.  The author noted that despite the increased use of lasers and other light-based therapies, few well-controlled studies have been conducted on their use for the treatment of rosacea.  Furthermore, a Cochrane review on interventions for rosacea (van Zuuren et al, 2005) concluded that the quality of studies evaluating rosacea treatments was generally poor.  There is evidence that topical metronidazole and azelaic acid are effective.  There is some evidence that oral metronidazole and tetracycline are effective.  There is insufficient evidence concerning the effectiveness of other treatments.  Good randomized controlled trials looking at these treatments are urgently needed.

Parodi et al (2011) stated that a range of treatment options are available in rosacea, which include several topical (mainly metronidazole, azelaic acid, other antibiotics, sulfur, retinoids) and oral drugs (mainly tetracyclines, metronidazole, macrolides).  In some cases, the first choice is a systemic therapy because patients may have sensitive skin and topical medications can be irritant.  Isotretinoin can be used in resistant cases of rosacea.  Unfortunately, the majority of studies on rosacea treatments are at high or unclear risk of bias.  A recent Cochrane review (van Zuuren et al, 2011) found that only topical metronidazole, azelaic acid, and oral doxycycline (40 mg) had some evidence to support their effectiveness in moderate-to-severe rosacea and concluded that further well-designed, adequately-powered randomized controlled trials are needed.  In the authors' practice, they evaluated their patients for the presence of 2 possible triggers, Helicobacter pylori infection and small intestinal bacterial over-growth.  When they are present, these clinicians use adapted antibiotic protocols.  If not, they use oral metronidazole or oral tetracycline to treat papulopustolar rosacea.  They also look for Demodex folliculorum infestation.  When Demodex concentration is higher than 5/cm(2), they use topical crotamiton 10 % or metronidazole.

Bamford et al (2012) noted that a 2006 article published in the International Journal of Dermatology reported that oral zinc sulfate 100 mg thrice-daily was associated with improvement in the severity of facial rosacea.  The current study was undertaken to further evaluate the role of zinc in the management of rosacea.  This was a randomized, double-blind trial of 220 mg of zinc sulfate twice-daily for 90 days in patients with moderately severe facial rosacea at baseline.  Subjects were recruited in the Upper Midwest USA between August 2006 and April 2008, and followed until July 2008.  A total of 44 subjects completed the trial (22 in each arm).  Rosacea improved in both groups.  There were no differences in magnitude of improvement based on rosacea severity scores between subjects receiving zinc sulfate and subjects receiving placebo (p = 0.284).  Serum zinc levels were higher in subjects receiving zinc (p < 0.001).  Oral zinc sulfate was not associated with greater improvement in rosacea severity compared with placebo in this study.  The authors stated that additional studies are needed to determine what role oral zinc may have in the management of rosacea.

Chang et al (2012) stated that papulopustular acne rosacea is a chronic inflammatory condition that can be difficult to treat.  Many patients are unwilling to use systemic medications, and single topical agents alone may not address all the symptoms of rosacea.  A combination topical clindamycin phosphate 1.2 % and tretinoin 0.025 % gel is efficacious for acne vulgaris, and may be helpful for rosacea, since acne vulgaris and rosacea shares many similar clinical and histologic features.  In a randomized, double-blind, placebo-controlled, 2-site pilot study, these investigators examined the safety and effectiveness of a combination gel consisting of clindamycin phosphate 1.2 % and tretinoin 0.025 % on papulopustular rosacea after 12 weeks of usage.  A total of 79 subjects with moderate-to-severe papulopustular acne rosacea using both physician and subjects' validated assessment tools wer included in this study.  Primary endpoint consisted of statistically significant reduction in absolute papule or pustule count after 12 weeks of usage.  There was no significant difference in papule/pustule count between placebo and treated groups after 12 weeks (p = 0.10).  However, there was nearly significant improvement in physicians' assessments of the telangiectasia component of rosacea (p = 0.06) and erythemato-telangiectatic rosacea subtype (p = 0.05) in treated versus placebo group after 12 weeks.  The only significant adverse event difference was facial scaling, which was significantly increased in treated group (p = 0.01), but this did not result in discontinuation of study drug.  The authors concluded that a combination gel of clindamycin phosphate 1.2 % and tretinoin 0.025 % may improve the telangiectatic component of rosacea and appears to better treat the erythemato-telangiectatic subtype of rosacea rather than papulopustular subtype.  They stated that these future studies with much larger sample size might confirm these preliminary findings.